I am pleased to announce an important milestone for JPI. On September 1, 2024, Jackpharma entered into an in-licensing agreement with Vendiz Pharmaceutical, Inc. (VPI) to exclusively market and distribute their entire product portfolio.
This in-licensing agreement will create a positive synergy that will grow our overall JPI business. It is an opportunity to grow our business with existing JPl customers, as well as develop new customers. It is also an opportunity to promote our JPI CORE brands to the existing customers of these Vendiz brands.
The VPI product portfolio consist of more than 17 brands that are currently available in the Philippine market. The most notable brands include DOXICON (Doxycycline 100mg), QUADROTOPIC CREAM 5gm tube & 500gm jars (clioquinol + tolnaftate + betamethasone + Gentamycin) and VITACLEAR (multivitamins + lutein + zinc + selenium). These brands are also available in Mercury and other trade outlets.
The other VPI in-licensed brands include Eye and Ear drops as well as dermatological creams consisting of anti-infectives, anti-fungal and steroid combinations. JPI shall continue to have Ashford Pharmaceutical Laboratory Inc. (APLI) to manufacture these Vendiz brands.
This is the fulfillment of my ONE DEGREE for 2024.
Sincerely,
Meny C. Hernandez
President
Jackpharma Inc.
Comments